Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma

European Journal of Cancer Prevention

Volumn 14, Issue 3, 2005, Pages 245-250

  Prawan, A ^a   Kukongviriyapan, V ^a   Tassaneeyakul, W ^a   Pairojkul, C ^a   Bhudhisawasdi, V ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Cholangiocarcinoma CYP1A2; NAT1; NAT2; Polymorphism

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE 1; ARYLAMINE ACETYLTRANSFERASE 2; CYTOCHROME P450 1A2; UNCLASSIFIED DRUG;

ACETYLATOR PHENOTYPE; ADULT; AGED; ALLELE; ARTICLE; BILE DUCT CARCINOMA; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; THAILAND;

ADULT; AGED; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; CYTOCHROME P-450 CYP1A2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISOENZYMES; LIVER NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 20344393397     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200506000-00008     Document Type: Article

References (35)

1. Bell DA, Taylor JA, Butler MA, et al. (1993). Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14: 1689-1692.
2. Bell DA, Badawi AF, Lang NP, et al. (1995a). Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 55: 5226-5229.
3. Bell DA, Stephens EA, Castranio T, et al. (1995b). Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 55: 3537-3542.
4. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH (1999). Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 58: 1759-1764.
5. Butler MA, Lang NP, Young JF, et al. (1992). Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2: 116-127.
6. Cascorbi I, Drakoulis N, Brockmoller J, et al. (1995). Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57: 581-592.
7. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999). Biliary tract cancers. N Engl J Med 341: 1368-1378.
8. de Leon JH, Vatsis KP, Weber WW (2000). Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol Pharmacol 58: 288-299.
9. Deitz AC, Doll MA, Hein DW (1997). A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal Biochem 253: 219-224.
10. Fukutome K, Watanabe M, Shiraishi T, et al (1999). N-Acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development. Cancer Lett 136: 83-87.
11. Green A, Uttaravichien T, Bhudhisawasdi V, et al. (1991). Cholangiocarcinoma in north east Thailand. A hospital-based study. Trop Geogr Med 43: 193-198.
12. Guengerich FP (1992). Metabolic activation of carcinogens. Pharmacol Ther 54: 17-61.
13. Han XM, Ouyang DS, Chen XP, et al. (2002). Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 54: 540-543.
14. Haswell-Elkins MR, Mairiang E, Mairiang P, et al. (1994). Cross-sectional study of Opisthorchis viverrini infection and cholangiocarcinoma in communities within a high-risk area in northeast Thailand. Int J Cancer 59: 505-509.
15. Hein DW (1988). Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948: 37-66.
16. Hein DW (2000). N-Acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis. Toxicol Lett 112-113: 349-356.
17. Hein DW, Doll MA, Fretland AJ, et al. (2000). Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9: 29-42.
18. Hirvonen A (1999). Polymorphic NATs and cancer predisposition. In: Vineis P, Malatus N, Lang M, et al. (editors): Metabolic Polymorphisms and Susceptibility to Cancer. Lyon: IARC Scientific Publication No. 148. IARC, pp. 251-270.
19. Kadlubar FF (1994). Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metab Rev 26: 37-46.
20. Katoh T, Inatomi H, Yang M, et al. (1999). Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese. Pharmacogenetics 9: 401-404.
21. Katoh T, Boissy R, Nagata N, et al. (2000). Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int J Cancer 85: 46-49.
22. Kukongviriyapan V, Prawan A, Tassaneyakul W, Aiemsa-Ard J, Warasiha B (2003a). Arylamine N-acetyltransferase-2 genotypes in the Thai population. Br J Clin Pharmacol 55: 278-281.
23. Kukongviriyapan V, Prawan A, Warasiha B, Tassaneyakul W, Aiemsa-ard J (2003b). Polymorphism of N-acetyltransferase 1 and correlation between genotype and phenotype in a Thai population. Eur J Clin Pharmacol 53: 277-281.
24. Landi MT, Zocchetti C, Bernucci I, et al. (1996). Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev 5: 693-698.
25. Lang NP, Butler MA, Massengill J, et al. (1994). Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 3: 675-682.
26. Nakajima M, Yokoi T, Mizutani M et al. (1999). Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 125: 803-808.
27. Ohshima H, Bartsch H (1994). Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 305: 253-264.
28. Sachse C, Brockmoller J, Bauer S, Roots I (1999). Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47: 445-449.
29. Shimoda K, Someya T, Morita S et al. (2002). Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 26: 261-265.
30. Sinha R, Rothman N, Brown ED, et al. (1994). Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res 54: 6154-6159.
31. Srivatanakul P, Ohshima H, Khlat M, et al. (1991). Opisthorchis viverrini infestation and endogenous nitrosamines as risk factors for cholangiocarcinoma in Thailand. Int J Cancer 48: 821-825.
32. Taylor JA, Umbach DM, Stephens E, et al. (1998). The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 58: 3603-3610.
33. Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S (1978). Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res 38: 4634-4639.
34. Vatanasapt V, Tangvoraphonkchai V, Titapant V, et al. (1990). A high incidence of liver cancer in Khon Kaen Province, Thailand. Southeast Asian J Trop Med Public Health 21: 489-494.
35. Weber WW, Hein DW (1985). N-Acetylation pharmacogenetics. Pharmacol Rev 37: 25-79.